Healthcare >> CEO Interviews >> October 12, 2001

Michael Flavin – Medichem Life Sciences (mcls)

MICHAEL T. FLAVIN is the Chairman and Chief Executive Officer of Advanced Life Sciences. He was the Founder, Chief Executive Officer and Chairman of MediChem Life Sciences. Dr. Flavin took MediChem from start-up in 1987 through many stages of development including the successful completion of MediChem's $35 million private placement with J.P. Morgan Capital Partners in 1999, the acquisition and integration of ThermoGen and Emerald Biostructures as MediChem subsidiaries and MediChem's October $54 million IPO. He also oversaw formation of the AXAS subsidiary and contract with the U.S. Department of Energy and management of the COMCAT beam line at the Advanced Photon Source at Argone National Laboratory. MediChem was acquired in 2002 by decode genetics for $83 million in stock. Dr. Flavin received a Bachelor of Science in Chemistry from the University of Illinois at Chicago, and completed a postdoctoral fellowship at Harvard University. Prior to Dr. Flavin's success at MediChem he worked as a Senior Research Associate for Baxter International. Dr. Flavin is also an Adjunct Professor for both the Graduate School of Business at Benedictine University and the Department of Medicinal Chemistry & Pharmacognosy at the University of Illinois at Chicago. Profile
TWST: Could you begin with a brief historical sketch of the company and

then an overview or picture of what the company is doing now?

Dr. Flavin: MediChem Life Sciences is a company that